Core Laboratories Inc. /DE/ financial statements

Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Core Laboratories Inc. /DE/ files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2021	FY2023	FY2023	FY2024	FY2025
Revenue	470	490	510	524	527
Cost of revenue		394	400	421	418
Gross profit		96.1	110	103	109
General and administrative		38.1	40.3	39.8	45.4
Operating income	45.3	41.5	54.6	58.6	56.5
Interest expense	9.15	11.6	13.4	12.4	10.6
Other non-operating income	-5.6	0.72	0.85	9.95	7.61
Pre-tax income	36.1	30	41.2	46.2	45.9
Income tax	15.9	10.3	4.19	14	15.5
Net income to minority interests	0.49	0.21	0.35	0.75	0.72
Net income	19.7	19.5	36.7	31.4	29.7
EBITDA	63.8	58.7	70.4	73.5	71.1
EPS, basic	0.43	0.42	0.79	0.67	0.64
EPS, diluted	0.42	0.42	0.77	0.66	0.63
Shares, basic (weighted)	46	46.3	46.7	46.9	46.4
Shares, diluted (weighted)	46.7	46.8	47.5	47.7	47
Dividend per share	0.04	0.04	0.04	0.04	0.04

Balance sheet

	FY2021	FY2023	FY2023	FY2024	FY2025
Cash and equivalents	17.7	15.4	15.1	19.2	22.7
Receivables		107	109	112	114
Inventory		60.4	71.7	59.4	54.5
Other current assets		5.06	5.09	10.5	6.94
Total current assets		212	223	221	215
Property, plant and equipment	111	105	99.6	97.1	99.4
Lease right-of-use assets		52.4	53.8	56.5	54.3
Goodwill		99.4	99.4	99.4	106
Intangible assets		7.48	6.93	6.4	7.12
Other non-current assets		33.7	34.2	34.8	35.3
Total assets	581	578	586	585	584
Accounts payable		45.8	33.5	34.5	37.3
Accrued liabilities		23.4	18.8	22.9	26.5
Deferred revenue		0.91	0.3	0.56
Total current liabilities		103	88.1	102	106
Long-term debt		172	163	126	110
Lease liabilities		38.3	42.1	43.3	42.3
Other non-current liabilities		20.9	20	20.7	15.8
Total liabilities		395	362	333	312
Total debt		175	166	128	113
Paid-in capital		102	110	110	110
Retained earnings		85.9	121	145	173
Treasury stock		-1.36	-1.45	-2.54	-11.6
Other comprehensive income		-3.78	-4.97	-5.77	-5.81
Shareholders' equity		184	225	247	266
Minority interests		4.7	4.99	5.75	6.22
Total equity	161	184	224	252	272
Total liabilities and equity		578	586	585	584
Shares outstanding		46.6	46.9	46.8	46.1

Cash flow statement

	FY2021	FY2023	FY2023	FY2024	FY2025
Net income	20.2	19.7	37	32.2	30.4
Depreciation and amortization	18.5	17.2	15.8	15	14.6
Stock-based compensation	19.1	7.76	14	3.76	7.14
Deferred income tax	6.71	-0.66	-11.1	0.62	1.4
Change in receivables	-13.5	-10.1	-2.62	-3.61	-4.95
Change in inventory	-4.55	-14.9	-13	9.37	2.64
Change in payables	6.57	15.4	-12.9	0.52	0.48
Cash from operations	36.6	25	24.8	56.4	37
Capital expenditures	-13.5	-10.2	-10.6	-11.9	-11.2
Acquisitions			0	0	-1.24
Cash from investing	-10.2	-3.86	-6.65	-6.39	-2.23
Debt issued	155	116	202	44	48
Debt repaid	-226	-131	-211	-82	-63
Stock issued	60	0	0
Share buybacks	-8.26	-3.9	-2.2	-5.31	-12.4
Dividends paid	-1.83	-1.85	-1.87	-1.88	-1.87
Cash from financing	-22.5	-23.4	-18.4	-46	-31.3
Net change in cash	3.9	-2.28	-0.31	4.04	3.55
Free cash flow	23	14.7	14.2	44.5	25.8
Interest paid	10.5	9.3	11.2	10.9	8.18
Income taxes paid	9.07	14.1	14.5	17.6	18.7

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.39 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	19.5%	Gross profit / revenue.
Operating margin	9.2%	Operating income / revenue.
EBITDA margin	12.1%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	7.1%	Pre-tax income / revenue.
Net margin	4.7%	Net income / revenue.
FCF margin	2.9%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	5.4%	Cash from operations / revenue.
Effective tax rate	32.9%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	8.9%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	4.2%	Net income / average total assets.
Return on invested capital (ROIC)	8.8%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	1.6%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	2.5%	Capital expenditures / revenue.
D&A / revenue	2.9%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	0.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	2.4%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y	5.4%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	4.3%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income growth, 1y	-3.6%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	10.8%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA growth, 1y	-3.3%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	6.6%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income growth, 1y	-5.5%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	15.1%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS growth, 1y	-4.5%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	14.5%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-34.3%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	14.1%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow growth, 1y	-42.0%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	20.5%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share growth, 1y	0.0%	Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y	0.0%	Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y	7.9%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	13.0%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y	-0.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	0.3%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y	-1.4%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.2%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.12x	Current assets / current liabilities.
Quick ratio	1.30x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.22x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.43x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	19.8%	Total debt / total assets.
Liabilities / assets	52.5%	Total liabilities / total assets.
Net debt	$93.6M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	1.49x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	4.35x	Operating income / interest expense.
Working capital	$113.3M	Current assets - current liabilities.
Goodwill and intangibles / assets	19.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	$160.1M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.88x	Revenue / average total assets.
Fixed asset turnover	5.17x	Revenue / average property, plant and equipment.
Inventory turnover	7.21x	Cost of revenue / average inventory.
Days inventory	51 days	365 x average inventory / cost of revenue.
Receivables turnover	4.77x	Revenue / average receivables.
Days sales outstanding	77 days	365 x average receivables / revenue.
Days payables	35 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	92 days	Days inventory + days sales outstanding - days payables.
FCF conversion	62.2%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	46.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.52	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$11.08	Revenue / diluted weighted shares.
FCF per share	$0.32	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.60	Cash from operations / diluted weighted shares.
Book value per share	$5.94	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$3.49	Tangible book value / shares outstanding.
Cash per share	$0.50	(Cash + short-term investments) / shares outstanding.
Payout ratio	7.6%	Dividends paid / net income, when net income is positive.
Dividends / FCF	12.2%	Dividends paid / free cash flow, when free cash flow is positive.
Buybacks / FCF	94.8%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$476.7M	Share price x shares outstanding.
Enterprise value	$570.4M	Market cap + total debt - cash - short-term investments.
P/E	19.6x	Market cap / net income. Only when net income is positive.
P/S	0.92x	Market cap / revenue.
P/B	1.75x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	2.98x	Market cap / tangible book value, when positive.
P/FCF	31.5x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	16.9x	Market cap / cash from operations, when positive.
EV/Sales	1.10x	Enterprise value / revenue.
EV/EBIT	11.9x	Enterprise value / operating income, when both are positive.
EV/EBITDA	9.10x	Enterprise value / EBITDA, when both are positive.
EV/FCF	37.7x	Enterprise value / free cash flow, when both are positive.
FCF yield	3.2%	Free cash flow / market cap.
Earnings yield	5.1%	Net income / market cap (the inverse of P/E).
Dividend yield	0.4%	Dividends paid over the period / market cap.
Shareholder yield	3.4%	(Dividends paid + share buybacks) / market cap.
PEG	1.35x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was Core Laboratories Inc. /DE/'s revenue in fiscal 2025?

Core Laboratories Inc. /DE/ reported revenue of $526.5M for fiscal 2025, 0.5% higher than the year before.

Was Core Laboratories Inc. /DE/ profitable in fiscal 2025?

Yes. Net income was $29.7M, a net margin of 5.6%.

How much free cash flow did Core Laboratories Inc. /DE/ generate in fiscal 2025?

Cash from operations of $37.0M minus capital expenditures of $11.2M left free cash flow of $25.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Core Laboratories Inc. /DE/